Compare Viatris Inc (VTRS) vs Wipro Limited (WIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Viatris Inc vs Wipro Limited — how do they compare? Viatris Inc trades at $16.45 (market cap $19.09B), while Wipro Limited trades at $1.69 (market cap $17.95B). The key difference: Viatris Inc and Wipro Limited are close in size by market cap, and Wipro Limited pays the higher dividend (5.01%). Which is the better fit depends on your goals.
| VTRS | WIT | |
|---|---|---|
Market Cap | $19.09B | $17.95B |
Sector | Health | Technology |
52-Week High | $17.86 | $3.06 |
52-Week Low | $9.49 | $1.68 |
Enterprise Value | $31.21B | $16.02B |
Dividend Yield | 2.89% | 5.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Viatris (VTRS) trades at $16.61, down 1.6% over the past 24 hours. The stock exhibits a mixed technical picture with a bullish overall signal but bearish moving averages. Fundamentally, the company reported a net loss of $3.51 billion in 2025 despite revenue of $14.30 billion, though recent quarters have shown earnings beats. Positive cash flow generation and a dividend payment highlight financial stability, while analyst sentiment is mixed with a majority hold rating.
The outlook for VTRS hinges on its ability to return to profitability and sustain operational improvements. Investment opportunities include strong cash flow, deleveraging progress, and pipeline developments, but risks involve persistent net losses, competitive pressures, and potential regulatory impacts from proposed generic drug tariffs.
WIT trades at $1.73, down 4.42% today, with bearish technical signals and mixed earnings performance. Recent quarters show earnings misses against expectations, though the company maintains strong profitability with 13.92% net margin and 16.09% ROE. Positive business developments include renewed partnerships with ABB and Databricks to enhance digital and AI services.
The outlook is cautious due to earnings volatility and bearish analyst sentiment, with only 19% buy ratings. Risks include competitive pressures and macroeconomic uncertainty affecting tech spending. The stock's valuation appears reasonable with P/E of 12.98, but investor confidence hinges on improved earnings consistency and margin stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →About Wipro Limited
Wipro is a leading global IT services provider, with 175,000 employees. Based in Bengaluru, this India IT services firm leverages its offshore outsourcing model to derive over half of its revenue (57%) from North America. The company offers traditional IT services offerings: consulting, managed services, and cloud infrastructure services as well as business process outsourcing as a service.
Read more on WIT →
